10-Q: BioLargo Reports Q2 2026 Results: Revenue Drops, Net Loss Widens

BioLargo, Inc. announced its Q2 2026 financial results, revealing a significant decrease in revenue and a widening net loss, alongside a negative working capital position.

Summary

• BioLargo, Inc. reported Q2 2026 results with total revenue of $1.248 million, a 55% decrease from $2.777 million in Q2 2025.
• The company experienced a net loss of $4.000 million for the quarter, compared to a net loss of $1.882 million in the prior year period.
• As of June 30, 2026, BioLargo had a working capital deficit of $1.266 million, with current liabilities of $4.765 million exceeding current assets of $3.499 million.
• The significant revenue decline is attributed to the cessation of private-labeled pet odor control product sales to Pooph Inc. in August 2025.
• The company's cash and cash equivalents decreased to $2.188 million from $3.883 million at the end of 2025.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern without further investment capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant revenue decline, increased net loss, and a substantial working capital deficit, raising going concern doubts.

Positives

• Service revenue increased by 7% to $827,000 in Q2 2026 compared to $771,000 in Q2 2025.
• BLEST, the engineering services division, saw a slight increase in third-party service revenue by 1% to $777,000 in Q2 2026.
• Clyra Medical generated its first revenue of $154,000 in the six months ended June 30, 2026, from the sale of ViaCLYR wound irrigation solution.
• The company received $4.469 million in net cash from financing activities during the first six months of 2026.

Negatives

• Total revenue for Q2 2026 was $1.248 million, a 55% decrease from $2.777 million in Q2 2025.
• Product revenue saw a significant 79% decrease, totaling $421,000 in Q2 2026 compared to $2.006 million in Q2 2025.
• Net loss for Q2 2026 was $4.000 million, a substantial increase from $1.882 million in Q2 2025.
• Operating loss for the quarter was $3.728 million, compared to $1.802 million in the prior year.
• Working capital deficit of $1.266 million as of June 30, 2026.
• Cash and cash equivalents decreased to $2.188 million from $3.883 million at the end of 2025.
• Management has raised substantial doubt about the company's ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is subject to substantial doubt due to its net loss, operating cash burn, and working capital deficit.
• The cessation of significant revenue streams (Pooph sales) poses a risk to future financial performance.
• The company requires further investment capital to fund its business plans and technology investments.
• Adverse outcomes in the ongoing legal proceedings with Pooph Inc. could materially impact future financial results.
• The long and technically intensive sales cycle for water treatment solutions presents a risk to revenue generation.

Future Outlook

The company expects to continue needing further investment capital to fund its business plans and technology investments, as gross profits are not anticipated to be sufficient to cover operational costs for the remainder of 2026. Management may curtail operations if additional cash cannot be raised.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern unless revenues increase, cash from operations is generated, and/or cash from financing activities is secured.
• If additional cash cannot be raised, management may choose to curtail portions of operations.
• The company is focused on redeploying its odor-control technology with new partners and expanding into new markets.
• The sales cycle for water and wastewater treatment projects is technically intensive, lengthy, and can take many months or even years.
• Management believes the company is well-positioned in the PFAS-removal market due to successful pilot studies, operational resilience, and strategic team additions.

Industry Context

StockSavvy.ai notes that the significant revenue decline is primarily due to the loss of a major private-label customer, highlighting the company's reliance on specific contracts. The company's focus on cleantech, including PFAS remediation and battery technology, aligns with growing market trends, but commercialization and sales cycles remain challenging.

Comparison to Industry Standards

• The company's revenue decline of 55% in Q2 2026 compared to Q2 2025 is a significant negative deviation from typical growth expectations for companies in the cleantech sector, which often aim for expansion.
• The net loss of $4.000 million in Q2 2026, widening from $1.882 million in Q2 2025, contrasts with industry leaders who are often achieving profitability or are on a clear path to it.
• The company's working capital deficit of $1.266 million raises concerns about short-term liquidity, a situation not typically seen in financially stable industry players.
• The lengthy sales cycle for water treatment solutions, described as potentially taking years for large projects, is a common challenge in this sector, but BioLargo's ability to navigate this is critical for its success compared to competitors with more established sales pipelines.
• The company's reliance on financing activities for cash flow, as evidenced by $4.469 million in net cash from financing in H1 2026, is common for early-stage technology companies but differs from mature companies that generate substantial operating cash flow.

Legal Proceedings

• ONM Environmental, Inc. is the defendant in a lawsuit filed by Pooph Inc. alleging Breach of Contract, Breach of Implied Covenant of Good Faith and Fair Dealing, and Declaratory judgment.
• BioLargo, Inc., BioLargo Life Technologies, Inc., and ONM Environmental, Inc. filed a lawsuit against Pooph, Inc. and Ikigai Marketing Works, LLC for patent infringement, false advertising, breach of contract, false promise, unfair and fraudulent business practices, and constructive fraud, seeking to recover $3,821,401 for unpaid product purchases and royalties.

Related Party Transactions

• Intercompany transactions and eliminations are noted in segment reporting.
• BioLargo owns 48% of Clyra Medical Technologies, Inc., 70% of BioLargo Engineering Science and Technologies, LLC (BLEST), 94% of BioLargo Energy Technologies, Inc. (BETI), and 78% of BioLargo Consumer Products Group, LLC (BCPG).
• Clyra Medical issued promissory notes totaling $1,064,000, of which $200,000 was issued to BioLargo.
• Clyra Medical's guaranteed note offering of $3,395,000 is guaranteed by BioLargo Inc.
• Clyra Medical's guaranteed promissory notes of $325,000 subsequent to June 30, 2026, are guaranteed by BioLargo Inc.

Stakeholder Impact

• Shareholders are impacted by the widening net loss, declining revenue, and the substantial doubt about the company's going concern status, which could lead to significant dilution or value erosion.
• Creditors may be concerned about the company's working capital deficit and its ability to meet short-term obligations.
• Employees may face uncertainty regarding job security if management decides to curtail operations due to lack of funding.
• Suppliers may experience delays in payments given the company's liquidity challenges.
• Customers of ONM Environmental may continue to receive odor control products and services, while customers of Clyra Medical may see new product offerings like ViaCLYR.

Next Steps

• Continue to pursue new partners for odor-control technology.
• Focus on commercializing the Cellinity battery technology through joint ventures.
• Advance the development and commercialization of the AEC PFAS treatment system.
• Continue to monitor evolving regulatory trends for advanced oxidation technologies.
• Seek additional investment capital to fund business plans and technology investments.

Key Dates

Recommendation

The significant revenue decline, widening net loss, negative working capital, and explicit mention of substantial doubt regarding the company's ability to continue as a going concern present a highly unfavorable financial picture. The company's reliance on financing activities and the cessation of a major revenue stream further exacerbate these concerns, suggesting a high risk for investors.

Keywords

BioLargo, 10-Q, Quarterly Report, Financial Statements, Results of Operations, Revenue, Net Loss, Working Capital